Dorndorf, Germany

Frank D Boehmer

This inventor holds 2 USPTO granted patents. Top assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2002-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank D Boehmer. Retrieved from https://idiyas.com/inventor/frank-d-boehmer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2002-2004

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Frank D Boehmer: Innovator in Pharmaceutical Compounds

Introduction

Frank D Boehmer is a notable inventor based in Dorndorf, Germany. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit PDGF receptor kinase. With a total of 2 patents to his name, Boehmer's work has implications for various therapeutic applications.

Latest Patents

Among his latest patents, Boehmer has focused on "PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same." This innovative work aims to provide new avenues for treating diseases associated with PDGF receptor activity.

Career Highlights

Frank D Boehmer is associated with the Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His role in this esteemed organization has allowed him to further his research and development efforts in the pharmaceutical sector.

Collaborations

Boehmer has collaborated with notable scientists such as Alexander Levitzki and Aviv Gazit. These partnerships have enriched his research and contributed to the advancement of his innovative projects.

Conclusion

Frank D Boehmer's contributions to the field of pharmaceutical compounds highlight his role as a significant inventor. His work continues to influence the development of new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…